1. Scrip
  2. >>Focus On Asia

Kangstem Soothes Investors, Finds Hope In New Trials For Furestem In Atopic Dermatitis

 
• By Jung Won Shin

After the much anticipated Phase III South Korean clinical trial of its cord blood-derived stem cell therapy for atopic dermatitis failed to meet its primary endpoint, Kangstem Biotech shifts tactics to focus on repeated dose and combo trials in the hope of better efficacy data.

Stem cell
Furestem-AD Fails To Meet Primary Endpoint, But Hopes Not Lost • Source: Shutterstock

Kangstem Biotech Co. Ltd. has announced disappointing top line results from a Phase III South Korean study with Furestem-AD, its human umbilical cord blood-derived mesenchymal stem cell (MSC) therapy for atopic dermatitis, but has assured investors that it will still complete development by focusing on repeated dose and combination trials.

Furestem-AD failed to meet statistical significance versus placebo against the primary endpoint of EASI (Eczema Area and Severity Index)-50 score at Week 12 in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.